FARMACIA HOSPITALARIA最新文献

{"title":"Salud digital para promover la adherencia al tratamiento antirretroviral en pacientes con VIH/sida: metarevisión","authors":"","doi":"10.1016/j.farma.2024.02.005","DOIUrl":"10.1016/j.farma.2024.02.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Digital health or “e-Health” is a set of applications based on Information and Communication Technologies that can be used to promote self-care and medication adherence in patients with chronic diseases. The aim of this study was to carry out a review of systematic reviews (meta-review) on efficacy studies of e-Health interventions to promote adherence to antiretroviral therapy in people living with HIV/AIDS.</p></div><div><h3>Method</h3><p>A review of systematic reviews (“meta-review”) was performed using the Medline-PubMed database on efficacy studies of e-Health components to promote adherence to antirretroviral therapy, in patients with HIV/AIDS, proposing a structured search strategy (PICO question). A selection process for systematic reviews was conducted based on inclusion and exclusion criteria. Subsequently, the corresponding data were extracted, and the analysis was accomplished in descriptive tables.</p></div><div><h3>Results</h3><p>A total of 29 systematic reviews were identified, from which 11 were selected. These reviews comprised 55 randomized controlled therapies with different e-Health interventions and enrolled a total of 15,311 HIV/AIDS patients. Studies included a total of 66 comparisons (experimental group vs. control group) in indirect adherence measurements based on different measurement techniques (36 statistically significant); 21 comparisons of viral load measurements (10 statistically significant); and 8 comparisons of CD4<!--> <!-->+ cell count measurements (3 statistically significant). m-Health was the most studied component followed by the telephone call and e-Learning.</p></div><div><h3>Conclusions</h3><p>Evidence was found that supports that some e-Health interventions are effective in promoting adherence to antirretroviral therapy and improving health outcomes in patients with HIV/AIDS, although it is identified that more studies are needed for more robust evidence.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000254/pdfft?md5=e4c6f639e26bb0e26bdfc649e31e32ce&pid=1-s2.0-S1130634324000254-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"El rol de la inteligencia artificial en la publicación científica: perspectivas desde la farmacia hospitalaria","authors":"","doi":"10.1016/j.farma.2024.06.002","DOIUrl":"10.1016/j.farma.2024.06.002","url":null,"abstract":"<div><p>The article examines the impact of artificial intelligence on scientific writing, with a particular focus on its application in hospital pharmacy. It analyzes artificial intelligence tools that enhance information retrieval, literature analysis, writing quality, and manuscript drafting.</p><p>Chatbots like <em>Consensus</em>, along with platforms such as <em>Scite</em> and <em>SciSpace</em>, enable precise searches in scientific databases, providing evidence-based responses and references. <em>SciSpace</em> facilitates the generation of comparative tables and the formulation of queries regarding studies, while <em>ResearchRabbit</em> maps the scientific literature to identify trends. Tools like <em>DeepL</em> and <em>ProWritingAid</em> improve writing quality by correcting grammatical, stylistic, and plagiarism errors. A.R.I.A. enhances reference management, and <em>Jenny AI</em> assists in overcoming writer's block. <em>Python</em> libraries such as <em>LangChain</em> enable advanced semantic searches and the creation of agents.</p><p>Despite their benefits, artificial intelligence raises ethical concerns including biases, misinformation, and plagiarism. The importance of responsible use and critical review by experts is emphasized. In hospital pharmacy, artificial intelligence can enhance efficiency and precision in research and scientific communication. Pharmacists can use these tools to stay updated, enhance the quality of their publications, optimize information management, and facilitate clinical decision-making.</p><p>In conclusion, artificial intelligence is a powerful tool for hospital pharmacy, provided it is used responsibly and ethically.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000965/pdfft?md5=83e271c9fe0c13e31659e0e4661a1b82&pid=1-s2.0-S1130634324000965-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceso para el acceso y formación del farmacéutico a la residencia en Farmacia Hospitalaria en Argentina","authors":"","doi":"10.1016/j.farma.2024.02.001","DOIUrl":"10.1016/j.farma.2024.02.001","url":null,"abstract":"<div><p>Hospital Pharmacy worldwide has proven to be a crucial element in healthcare. In Latin America, it draws inspiration from two main models: United States, which promoted clinical pharmacy and later pharmaceutical care, and Spain, which shares similar healthcare practices and the added advantage of a common language. Both models influenced the implementation of Hospital Pharmacy residencies in Argentina since the 1980s.</p><p>Hospital Pharmacy residencies in Argentina constitute a paid system of intensive postgraduate training on a full-time basis with exclusive dedication. They are carried out in 11 provinces across Argentina in services with recognized teaching experience. Currently, there are 46 locations with a total of 75 annual vacancies for applicants.</p><p>The objective of Hospital Pharmacy residencies is to train pharmaceutical professionals with the necessary competencies to ensure the care of patients through the optimization of the safe, effective, and efficient use of medications and healthcare products tailored to each patient’s individual therapy.</p><p>Hospital Pharmacy residencies have demonstrated that pharmacists acquire specialized training that can be decisive in influencing healthcare policies related to the safe use of medications and healthcare products. Therefore, actions to promote and encourage interest in this field among pharmaceutical professionals are necessary, involving scientific societies, universities, pharmaceutical associations, and the political sphere.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000217/pdfft?md5=c250230defface57817ffeef051166f0&pid=1-s2.0-S1130634324000217-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concordance between two models of stratification for patients living with HIV infection to providing pharmaceutical care","authors":"","doi":"10.1016/j.farma.2024.01.009","DOIUrl":"10.1016/j.farma.2024.01.009","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the degree of agreement of 2 differents stratification models for pharmaceutical care to people living with HIV.</p></div><div><h3>Methods</h3><p>This was a single-center observational prospective cohort study of patients with regular follow-up in pharmaceutical care consultations according to the Capacity–Motivation–Opportunity methodology, conducted between January 1 and March 31, 2023.</p><p>Patients received the pharmacotherapeutic interventions applied routinely to ambulatory care patients according to this model. As part of the usual clinical practice, the presence or absence of the variables that apply to both stratification models were collected.</p><p>The scores obtained and the corresponding stratification level were collected for each patient according to both stratification models published (ST-2017 and ST-2022).</p><p>To analyze the reliability between the measurements of 2 numerical score models of the stratification level with both tools, their degree of concordance was calculated using the intraclass correlation coefficient. Likewise, reliability was also evaluated from a qualitative perspective by means of Cohen's Kappa coefficient.</p><p>Additionally, the existence of correlation between the scores of the 2 models was assessed by calculating Pearson's correlation coefficient.</p></div><div><h3>Results</h3><p>Of the total of 758 patients being followed in the cohort, finally, 233 patients were enrolled. The distribution of patients for each stratification model was: ST-2017: 59.7% level-3, 25.3% level-2, and 15.0% level-1, while for ST-2022: 60.9% level-3, 26.6% level-2, and 12.4% level-1.</p><p>It was observed that the reclassification was symmetrical (<em>P</em> <!-->=<!--> <!-->.317). The qualitative analysis of the agreement between the models showed a good Cohen's kappa value, (K<!--> <!-->=<!--> <!-->0.66). A value of 0.563 was found as the intraclass correlation coefficient.</p><p>Finally, the correlation analysis between the quantitative scores of the 2 models yielded a Pearson correlation coefficient of 0.86.</p></div><div><h3>Conclusions</h3><p>The concordance between the 2 models was good, which confirms that the multidimensional adaptation and simplification of the model were correct and that its use can be extended in routine clinical practice.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000205/pdfft?md5=a9cdb429d50e32b384d2a6c4720e9f12&pid=1-s2.0-S1130634324000205-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Documento nacional de consenso de monitorización terapéutica de antibióticos y antifúngicos en el paciente pediátrico y neonatal de la Sociedad Española de Farmacia Hospitalaria (SEFH) y la Sociedad Española de Infectología Pediátrica (SEIP)","authors":"Sonia Luque ,&nbsp;Natalia Mendoza-Palomar ,&nbsp;David Aguilera-Alonso ,&nbsp;Beatriz Garrido ,&nbsp;Marta Miarons ,&nbsp;Ana Isabel Piqueras ,&nbsp;Enrique Tévar ,&nbsp;Eneritz Velasco-Arnaiz ,&nbsp;Aurora Fernàndez-Polo","doi":"10.1016/j.farma.2024.02.012","DOIUrl":"10.1016/j.farma.2024.02.012","url":null,"abstract":"<div><p>Therapeutic monitoring of antibiotics and antifungals based on pharmacokinetic and pharmacodynamic parameters, is a strategy increasingly used for the optimization of therapy to improve efficacy, reduce the occurrence of toxicities, and prevent the selection of antimicrobial resistance, particularly in vulnerable patients including neonates and the critical or immunocompromised host.</p><p>In neonates and children, infections account for a high percentage of hospital admissions and anti-infectives are the most used drugs. However, pediatric pharmacokinetic and pharmacodynamic studies and the evidence regarding the efficacy and safety of some newly marketed antibiotics and antifungals -usually used off-label in pediatrics- to determine the optimal drug dosage regimens are limited. It is widely known that this population presents important differences in the pharmacokinetic parameters (especially in drug clearance and volume of distribution) in comparison with adults that may alter antimicrobial exposure and, therefore, compromise treatment success. In addition, pediatric patients are more susceptible to potential adverse drug effects and they need closer monitoring.</p><p>The aim of this document, developed jointly between the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Pediatric Infectious Diseases (SEIP), is to describe the available evidence on the indications for therapeutic drug monitoring of antibiotics and antifungals in newborn and pediatric patients and to provide practical recommendations for therapeutic drug monitoring in routine clinical practice to optimize pharmacokinetic and pharmacodynamic parameters, efficacy and safety of antibiotics and antifungals in the pediatric population.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000333/pdfft?md5=8ea0f5f593a4c2fa6685fb234359729a&pid=1-s2.0-S1130634324000333-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Asciminib para el tratamiento de la leucemia mieloide crónica en tercera línea: análisis coste-efectividad basado en el enfoque de remisión libre de tratamiento","authors":"Antonio García Molina","doi":"10.1016/j.farma.2024.06.004","DOIUrl":"10.1016/j.farma.2024.06.004","url":null,"abstract":"<div><h3>Introduction</h3><p>The first targeted therapy in oncology, imatinib, revolutionized chronic myeloid leukemia (CML) treatment and spurred research in targeted therapies for various cancers. CML results from a chromosomal translocation, forming the BCR-ABL1 fusion gene. Asciminib has been recently approved for 3rd-line refractory or intolerant patients. Treatment-free remission (TFR) is attainable with sustained deep molecular response (DMR) and this approach could be incorporated into pharmacoeconomic models.</p></div><div><h3>Aims</h3><p>To establish a cost-effectiveness model comparing asciminib to approved third-generation tyrosine kinase inhibitors (TKIs) (bosutinib and ponatinib) with a focus on achieving TFR. Additionally, the budgetary impact of incorporating asciminib as a therapeutic alternative is assessed.</p></div><div><h3>Methods</h3><p>This model is based on a Markov chain with seven states. The condition for achieving TFR is to remain for 5 years in DMR state. Efficacy of the model was measured in QALYs, and the costs included in the base case analysis are based in Spain. A probabilistic (PSA) and deterministic analysis (DSA) were carried out to assess the variability of the model. There were achieved two independent models comparing asciminib vs. bosutinib and asciminib vs. ponatinib.</p></div><div><h3>Results</h3><p>Asciminib, when compared with ponatinib, is a cost-saving alternative, as efficacy is similar between alternatives, and asciminib has a lower cost of 30,275 €. Asciminib showed 4.33 more QALYs and a higher cost (203,591 €) than bosutinib, resulting in an ICER of €47,010.49 per QALY. PSA shows that the parameters with higher influence in the variability of the model were the probability of transitioning to BP and probabilities of achieving MMR and DMR. A one-way analysis reports that the drug cost has a higher influence on both models, and the discount rate significantly affects the asciminib vs. bosutinib model.</p></div><div><h3>Conclusion</h3><p>Asciminib broadens therapeutic choices for patient’s refractory or intolerant to two prior lines of treatment in a cost-effective manner. The costs of drugs significantly impact the overall cost of the disease, emphasizing the importance of the selected discount rates for each drug. Given the relatively low incidence of CML, the introduction of asciminib has a limited budgetary impact, warranting individualized decisions based on patient`s clinical characteristics.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324001004/pdfft?md5=92f0167a0735bdabdbdfc32e203c6884&pid=1-s2.0-S1130634324001004-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141628059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Pharmaceutical recommendations for therapeutic appropriateness in patients with multiple sclerosis","authors":"","doi":"10.1016/j.farma.2024.05.002","DOIUrl":"10.1016/j.farma.2024.05.002","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the prevalence of PIMDINAC criteria and to implement pharmacological interventions in a population with multiple sclerosis over 55 years of age.</p></div><div><h3>Methods</h3><p>Retrospective, observational, open-label study, including patients with multiple sclerosis aged 55 years and older during December 2022 and February 2023. The main variable determined was the percentage of compliance with the PIMDINAC criteria.</p></div><div><h3>Results</h3><p>Ninety-five patients were included, with the presence of PIMDINAC criteria detected in 67.4%. The most frequently detected criterion was non-adherence to concomitant treatment (84.4%), followed by drug–drug interactions (56.2%) and potentially inappropriate medication (25%). A total of 20 pharmaceutical interventions were performed in 17 patients (17.9%). Potentially inappropriate medication was responsible for 11 interventions, non-adherence for 7, and drug–drug interactions for 2. The 81.8% of interventions were accepted, resulting in the discontinuation of 15 inappropriately prescribed drugs. The prevalence of PIMDINAC criteria in this group of patients is high. The study revealed that PIMDINAC criteria were prevalent in 67.4% of the study population, with polypharmacy playing an important role, suggesting the potential for a multidisciplinary approach, through pharmaceutical interventions to address unnecessary or duplicate treatments.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000825/pdfft?md5=745085a1f64de0bcae13ca40557da073&pid=1-s2.0-S1130634324000825-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Concordancia entre 2 modelos de estratificación de pacientes que viven con el VIH para la prestación de atención farmacéutica","authors":"","doi":"10.1016/j.farma.2024.05.007","DOIUrl":"10.1016/j.farma.2024.05.007","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the degree of agreement of two differents stratification models for pharmaceutical care to people living with HIV.</p></div><div><h3>Methods</h3><p>This was a single-centre observational prospective cohort study of patients with regular follow-up in pharmaceutical care consultations according to the Capacity-Motivation-Opportunity methodology, conducted between January 1st and March 31th, 2023.</p><p>Patients received the pharmacotherapeutic interventions applied routinely to ambulatory care patients according to this model. As part of the usual clinical practice, the presence or absence of the variables that apply to both stratification models were collected.</p><p>The scores obtained and the corresponding stratification level were collected for each patient according to both stratification models published (ST-2017 and ST-2022).</p><p>To analyze the reliability between the measurements of two numerical score models of the stratification level with both tools, their degree of concordance was calculated using the intraclass correlation coefficient. Likewise, reliability was also evaluated from a qualitative perspective by means of Cohen's Kappa coefficient.</p><p>Additionally, the existence of correlation between the scores of the two models was assessed by calculating Pearson's correlation coefficient.</p></div><div><h3>Results</h3><p>Of the total of 758 patients being followed in the cohort, finally, 233 patients were enrolled. The distribution of patients for each stratification model was: ST-2017: 59.7% level-3, 25.3% level-2 and 15.0% level-1, while for ST-2022: 60.9% level-3, 26.6% level-2 and 12.4% level-1.</p><p>It was observed that the reclassification was symmetrical (<em>p</em> <!-->=<!--> <!-->0.317). The qualitative analysis of the agreement between the models showed a good Cohen's kappa value, (K<!--> <!-->=<!--> <!-->0.66). A value of 0.563 was found as the intraclass correlation coefficient.</p><p>Finally, the correlation analysis between the quantitative scores of the two models yielded a Pearson correlation coefficient of 0.86.</p></div><div><h3>Conclusions</h3><p>The concordance between the two models was good, which confirms that the multidimensional adaptation and simplification of the model were correct and that its use can be extended in routine clinical practice.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000874/pdfft?md5=f47ade39832e8d3f959abb2c44383b41&pid=1-s2.0-S1130634324000874-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recomendaciones farmacéuticas de adecuación terapéutica en pacientes con esclerosis múltiple","authors":"","doi":"10.1016/j.farma.2024.02.015","DOIUrl":"10.1016/j.farma.2024.02.015","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the prevalence of PIMDINAC criteria and to implement pharmacological interventions in a population with multiple sclerosis over 55 years of age.</p></div><div><h3>Methods</h3><p>Retrospective observational open-label study including patients with multiple sclerosis aged 55 years and older between December 2022 and February 2023. The main variable determined was the percentage of compliance with the PIMDINAC criteria.</p></div><div><h3>Results</h3><p>Ninety-five patients were included, with the presence of PIMDINAC criteria detected in 67.4%. The most frequently detected criterion was non-adherence to concomitant treatment (84,4%), followed by drug–drug interactions (56.2%) and potentially inappropriate medication (25%). A total of 20 pharmaceutical interventions were performed in 17 patients (17.9%). Potentially inappropriate medication was responsible for 11 interventions, non-adherence for 7 and drug–drug interactions for 2. The 81.8% of interventions were accepted, resulting in the discontinuation of 15 inappropriately prescribed drugs. The prevalence of PIMDINAC criteria in this group of patients is high. The study revealed that PIMDINAC criteria were prevalent in 67.4% of the study population, with polypharmacy playing an important role, suggesting the potential for a multidisciplinary approach, through pharmaceutical interventions to address unnecessary or duplicate treatments.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000369/pdfft?md5=a8a60f0b73eabd5f45b333998c4cc0d6&pid=1-s2.0-S1130634324000369-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calidad de vida percibida por los pacientes con psoriasis tratados con inhibidores de interleucina 17 y 23","authors":"","doi":"10.1016/j.farma.2024.01.004","DOIUrl":"10.1016/j.farma.2024.01.004","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors.</p></div><div><h3>Method</h3><p>Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively.</p></div><div><h3>Results</h3><p>Forty-one patients were included: 65% male, median age 54 years (SD<!--> <!-->=<!--> <!-->13). The included patients were treated with ixekizumab 35%, guselkumab 25%, secukinumab 17.5%, brodalumab 15% and risankizumab 7.5%.</p><p>Psoariasis area severity index (PASI) reduction was 94.6% (RIC 76.8-100%), DLQI of 1 (RIC 0-2.75), DLQI ≤ 1, 60%. The most affected health dimensions were symptoms and perceptions (57.5%), activities of daily living (27.5%) and discomfort caused with treatment (17.5%). No association was found between DLQI score &lt; 1 and demographic, comorbidities and treatment-related variables. The median PASI reduction in patients with DLQI<!--> <!-->&lt;<!--> <!-->1 was superior to patients with DLQI &gt; 1 (100% vs 90.2%, <em>p</em> <!-->=<!--> <!-->0.025).</p></div><div><h3>Conclusions</h3><p>Patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors achieve adequate therapeutic targets achieving the target set according to clinical practice guideline recommendations (score ≤<!--> <!-->1 on the DLQI questionnaire and 90-100% reduction in the PASI index) and in accordance with the results of recent meta-analyses and real-life studies.</p><p>A greater reduction of the PASI index is observed in the group reaching the quality of life target, there being the possibility of using patient-reported outcomes in the evaluation of treatment effectiveness.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000163/pdfft?md5=dd84b7912ae24b5fdf3515610a3dc245&pid=1-s2.0-S1130634324000163-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}